Back

Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: ASPIRE (efficacy and safety of apixaban in real-world practice in Korean frail patients with AF)

25 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Prognosis and outcome in patients with atrial fibrillation Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Jungmin Choi

Seoul National University Hospital, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Cigarette smoking and structural brain deficits in patients with atrial fibrillation
Mr R. Peter (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The current and future total health care costs of atrial fibrillation
Doctor R. Sandhu (Calgary, CA)
Abstract Slides Video
Presentation thumbnail
Association of atrial fibrillation burden with rhythm control and stroke prevention interventions among patients with cardiac implantable electronic devices
Doctor G. Peigh (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Risk differences between atrial fibrillation patients with different clinical phenotypes: insights from the French population
Doctor A. Fawzy (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension is an adverse risk factor for peri-procedural complications in patients undergoing cardioversion for atrial fibrillation
Doctor M. Kodali (Milwaukee, US)
Abstract Slides

Access the full session

Session thumbnail
Prognosis and outcome in patients with atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban
thumbnail
Congress Presentation
Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources